Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$954K Sell
6,564
-193
-3% -$26.7K 0.25% 83
2026
Q2
$868K Buy
6,757
+309
+5% +$36.2K 0.24% 89
2026
Q1
$776K Buy
6,448
+654
+11% +$75.5K 0.24% 88
2025
Q4
$610K Buy
5,794
+17
+0.3% +$1.6K 0.2% 97
2025
Q3
$485K Sell
5,777
-15,693
-73% -$1.29M 0.16% 108
2025
Q2
$1.7M Sell
21,470
-1,084
-5% -$86.2K 0.62% 55
2025
Q1
$2.02M Buy
22,554
+5,289
+31% +$494K 0.84% 36
2024
Q4
$1.72M Buy
+17,265
New +$1.78M 0.85% 39

Other funds holding MRK

TFR Capital's MRK Position: Q3 2026 in Review

TFR Capital reduced its Merck (MRK) stake by 2.9% in Q3 2026, selling an estimated $26.7K and leaving 6,564 shares worth $954K. The position accounts for 0.25% of the portfolio, ranked #83.

TFR Capital first reported a position in MRK in Q4 2024 and has held it in 8 quarters since. The position peaked at $2.02M in Q1 2025. 2,771 funds tracked by Wall St. Rank hold MRK as of Q3 2026.

  • TFR Capital held 6,564 shares of Merck worth $954K as of Q3 2026.
  • TFR Capital sold 193 Merck shares in Q3 2026, an estimated $26.7K.
  • Merck made up 0.25% of TFR Capital's portfolio in Q3 2026, its #83 holding.
  • TFR Capital first reported a position in Merck in Q4 2024 and has held it in 8 quarters since.
  • TFR Capital's Merck position peaked at $2.02M in Q1 2025.
  • 2,771 funds tracked by Wall St. Rank held Merck as of Q3 2026.

Based on TFR Capital's 13F filing for Q3 2026, filed 9 Nov 2026.